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Intracellular drug concentrations are fundamentally important 
to drug efficacy and toxicity as well as for understanding and 
accurately predicting drug interactions and intersubject vari-
ability in drug response (either on-target or off-target effects). 
Intracellular drug concentrations are difficult to quantify 
directly in humans. Therefore, blood or plasma drug concen-
trations are typically used as a surrogate measure under the 
assumption that unbound drug concentrations in the systemic 
circulation mirror intracellular unbound drug concentrations 
at the site of action. This assumption is based on the free-drug 
hypothesis, i.e., that unbound drug concentrations on either 
side of a membrane are in thermodynamic equilibrium.1 
However, this assumption may not be valid for many drugs, 
especially those that are poorly permeable (e.g., charged or 
polar compounds), actively transported, or extensively metabo-
lized in vivo. Uncertainty regarding the actual unbound intra-
cellular concentration of drugs makes it difficult to predict in 
vivo effects that depend on interactions between the unbound 
drug and intracellular targets.
The efficacy of drugs for which the target site is the liver 
will be directly affected by unbound hepatic drug concentra-
tions. For example, the liver is the target organ for statins. 
Statin efficacy is influenced by hepatocellular statin concen-
trations, which may be modulated by hepatic transport and/
or metabolism processes.2 Regardless of the location of the 
target site, the ability of a drug to exert a sustained pharma-
cologic effect may be limited owing to rapid removal from 
the systemic circulation by eliminating organs (e.g., liver). 
The hepatic clearance of drugs depends on the intracellular 
unbound concentration at the site of metabolism or transport. 
In addition, intracellular unbound concentrations of drugs/
metabolites in relevant tissues may be important parameters 
for drug-induced toxicities. For instance, inhibition of the 
bile salt export pump (BSEP/ABCB11) is one hypothesized 
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mechanism of drug-induced liver injury.3 Because BSEP 
mediates bile acid efflux across the canalicular membrane, 
knowledge of unbound hepatocyte concentrations of BSEP 
inhibitors is critical for predicting BSEP-related cholestasis in 
humans.4 Similarly, accurate predictions of drug–drug inter-
actions (DDIs) caused by inhibition or induction of metabolic 
enzymes require knowledge of unbound hepatocyte concen-
trations of the potential perpetrators. If the perpetrators are 
substrates for hepatic uptake transporters, cytochrome P450 
(CYP)-mediated DDIs are often underpredicted on the basis 
of unbound plasma concentrations of inhibitors.5
This white paper highlights the state of the art of the deter-
minants of intracellular drug concentrations. The discussion 
includes (i) a review of fundamental concepts regarding fac-
tors that influence drug concentrations in hepatocytes, (ii) an 
overview of important hepatic transporters and examples of 
how these proteins may affect hepatocyte drug concentrations, 
(iii) experimental and modeling approaches that may be used 
to estimate intracellular drug concentrations, and (iv) current 
challenges and recommendations regarding the determination 
of unbound drug concentrations in hepatocytes during the pro-
cess of drug development.
FACTORS THAT INFLUENCE INTRACELLULAR DRUG 
 DISPOSITION IN THE LIVER
The intracellular unbound drug concentration in hepatocytes 
is influenced by hepatic physiology and the physicochemical 
properties of a drug. In contrast to the common simplifica-
tion of its role, the liver is not merely a well-stirred compart-
ment. At the organ level, drug concentrations in the hepatic 
microvasculature may vary between different parts of the liver 
depending on the mixing of portal and venous blood (Figure 
1), and zonal differences in metabolism and biliary excretion. 
Thus, hepatocytes may be exposed to different drug concen-
trations depending on their location in the sinusoid. The rate 
and extent of drug movement into hepatocytes are affected 
by local concentrations in the sinusoid and may be limited 
by either permeability across the basolateral membrane or 
hepatic blood flow.6 Plasma protein and tissue binding may 
affect intracellular unbound drug concentrations.1 Within 
the hepatocyte, hepatocellular drug exposure is determined 
by (i) the rate and extent of uptake into the hepatocyte and 
(ii) the rate and extent of removal from the cell (Figure 2). 
Several processes are involved in intracellular drug exposure, 
including passive diffusion (described by the passive diffu-
sion clearance, CLdiff), transporter-mediated basolateral 
uptake (intrinsic basolateral uptake clearance, CLact,uptake) 
and efflux (intrinsic basolateral efflux clearance, CLact,efflux), 
biliary excretion (intrinsic biliary excretion clearance, CLbile), 
and hepatic metabolism (intrinsic metabolic clearance, CLmet; 
Figure 2a,b).7,8 The impact of these processes on intracellular 
drug exposure is described in more detail below.
In addition to transport and metabolism processes, which 
determine overall cellular drug exposure, intracellular bind-
ing and partitioning (described by the unbound fraction in 
the liver, fu,liver, and the cellular partition coefficient based 
on total concentrations, Kp) and sequestration into sub-
cellular organelle compartments (e.g., lysosomes or mito-
chondria) can affect the fraction of drug that is available 
for intracellular pharmacological action, metabolism, and 
excretion (Figure 2a). However, under steady-state condi-
tions, unbound cytosolic drug concentration is determined 
by the intrinsic uptake and elimination clearances, and any 
intracellular binding and partitioning will affect the unbound 
drug fraction (because the total intracellular concentration is 
increased) but will have no effect on unbound cytosolic drug 
concentration.1
Kpuu,liver is defined as the steady-state liver-to-sinusoidal 
blood partition coefficient for unbound drug, typically under 
the assumption that the liver is a “well-stirred” homogeneous 
compartment. As such, unbound liver concentration refers to 
unbound concentration in the cytosol. Kpuu,liver is a function of 
CLdiff, CLact,uptake, CLact,efflux, CLbile, and CLmet. CLdiff is driven 
by transmembrane concentration gradients and is linked closely 
to the drug’s physicochemical properties, such as lipophilicity 
(typically described by the octanol-water partition coefficient 
(logP/logD)), polarity, molecular size, and degree of ionization 
at physiological pH (pKa). Higher CLdiff values are generally 
observed for smaller, more lipophilic, un-ionized compounds. 
For compounds for which CLdiff is much greater than other 
intrinsic clearance values, Kpuu,liver approximates 1. In such cases, 
intracellular hepatic concentrations will be determined primarily 
by the metabolic and/or biliary excretion clearances. If meta-
bolic or efflux clearance values are larger than CLdiff and hepatic 
uptake is determined primarily by CLdiff, then Kpuu,liver can be 
<1. By contrast, for compounds with low CLdiff, transporter-
mediated CLact,uptake will have a greater impact on intracellular 
concentration and Kpuu,liver can be >1.9,10 The impact of altered 
transport on the intracellular concentration and exposure of 
Figure 1 Microanatomy of the liver. Hepatocytes, bile ductules, and  
sinusoids are represented. The structure of a hepatocyte is depicted with its 
apical, basal, and lateral sides. The sinusoid is depicted to highlight the fact 
that the blood is not well mixed in the sinusoid.
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these types of compounds is summarized in Table 1 and is dis-
cussed in more detail below (refs. 76–98, cited in the table, can 
be found in the Supplementary Data online).
It should be noted that the partition coefficient Kp based 
on total concentrations can deviate from unity even in the 
absence of transporter and metabolism effects. In particular, 
for lipophilic compounds, partitioning among cellular mem-
branes and other cell structures can result in a Kp value that 
is orders of magnitude greater than unity. In addition, elec-
trochemical and pH gradients across the plasma membrane 
and internal (organelle) membranes can result in preferential 
subcellular distribution of drug molecules based on charge 
and ionization potential. For example, lysosomal pH is gener-
ally 1–2 units lower than the cytosol pH. As a consequence, 
drugs with weakly basic properties that are predominantly 
uncharged in the cytosol will become charged upon entering 
the lysosome, effectively trapping these compounds because 
of the limited permeability of the charged molecular spe-
cies. Such pH-driven lysosomal sequestration is saturable, is 
dependent on adenosine triphosphate (ATP)(because the pH 
gradient is maintained by membrane-bound ATPases), and can 
result in several-fold increases in Kp.11–13 Similarly, the inner 
mitochondrial membranes possess a negative transmembrane 
electrical potential relative to the cytosol, which can result 
in the trapping of positively charged drug molecules.11,14,15 
Sequestration within lysosomes and mitochondria can trans-
late to considerable local drug concentrations in these orga-
nelles and potentially cause changes in on- target or off-target 
effects within hepatocytes, which may have pharmacological 
and/or toxicological implications that cannot be predicted 
based solely on systemic concentrations.
Given that drug concentrations in each subcellular com-
partment can vary as discussed above, it is noteworthy that the 
definition of “intracellular drug concentrations” is obscure. In 
this white paper, the term “intracellular drug concentrations” 
denotes unbound drug concentrations in the cytosol (also 
referred to as unbound hepatocellular drug concentrations) 
and the term “subcellular drug concentrations” signifies drug 
concentrations in various subcellular compartments.
IMPACT OF TRANSPORTERS AND ENZYME–TRANSPORTER 
INTERPLAY ON HEPATIC DRUG CONCENTRATIONS
The liver is the major organ responsible for drug metabolism and 
excretion. Not surprisingly, membrane transporters that influ-
ence hepatic intracellular concentrations can have a major impact 
on the overall disposition of drugs as well as their efficacy and 
toxicity. The cellular localization of key human hepatic transport 
proteins is depicted schematically in Figure 2c. Transporters in 
the basolateral membrane mediate the uptake of substrates from 
blood into the hepatocyte and/or efflux of substrates in the oppo-
site direction; transporters in the canalicular membrane mediate 
the excretion of substrates into bile; and transporters in the intra-
cellular membranes sequester substrates in subcellular compart-
ments within hepatocytes. The examples below and summarized 
in Table 1 demonstrate how these transport proteins have the 
potential to affect intracellular and systemic (plasma) exposure 
of substrates, including endogenous compounds, drugs, and/or 
metabolites.
Figure 2 Factors affecting intracellular drug concentrations in the hepatocyte. (a) Processes affecting intracellular drug concentrations are depicted. (1) 
Drug in the blood that is not associated with blood cells or plasma proteins can enter the hepatocyte (2) through passive diffusion or (3) via active uptake 
mediated by basolateral uptake transporters. Within the hepatocytes, (4,5) the drug can bind to intracellular structures (e.g., proteins, DNA, and membranes) 
or (6) partition into subcellular organelles such as mitochondria or lysosomes via a combination of carrier-mediated transport and/or passive diffusion driven 
by the electrochemical membrane potential and the pH gradient. Based on the free-drug hypothesis, only the unbound drug in the hepatocyte can undergo 
(7) efflux back to sinusoidal blood via the action of basolateral efflux transporters, (8) enzymatic biotransformation, or (9) excretion into the bile mediated by 
canalicular efflux transporters. (b) Passive and active clearance processes affecting hepatocyte intracellular concentrations. CLact,efflux, intrinsic active efflux 
clearance; CLact,uptake, intrinsic active uptake clearance; CLbile, intrinsic biliary excretion clearance; CLdiff, passive diffusion clearance; CLmet, intrinsic metabolic 
clearance; fu,b, unbound fraction of drug in the blood; fu,cell, unbound fraction of drug in cell; fu,ISF , unbound fraction of drug in interstitial fluid. (c) Membrane 
localization of key uptake and efflux transporters that may affect hepatocyte intracellular concentrations. The schematic representation is limited to 
transporters expressed in the plasma membrane that have previously shown effects on drug disposition and toxicity and could potentially modulate unbound 
drug concentrations in the liver.
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Decreased hepatocyte concentrations due to impaired 
hepatic uptake
At a given plasma concentration, impaired function of a baso-
lateral uptake transport protein as a result of a genetic poly-
morphism or a DDI would be expected to decrease hepatocyte 
concentrations of a drug if its hepatic uptake depends solely, 
or primarily, on that basolateral uptake transporter. For exam-
ple, gadoxetate disodium, an extracellular magnetic resonance 
imaging (MRI) contrast agent, is transported by organic anion–
transporting polypeptide 1B1 (OATP1B1/SLCO1B1), OATP1B3 
(SLCO1B3), and Na+-taurocholate–cotransporting polypep-
tide (SLCO10A1) into hepatocytes.16 Lapatinib, an inhibitor 
of OATP1B1, significantly decreases hepatic parenchymal 
enhancement of gadoxetate disodium–enhanced MRI scans, 
potentially compromising the ability to diagnose liver tumors 
using this imaging agent.17 Similarly, the glucose-lowering 
effects of metformin would be expected to be dependent on its 
hepatic exposure. Metformin is a substrate for the basolateral 
uptake organic cation transporter 1 (OCT1/SLC22A1) and 2 
(OCT2/SLC22A2), expressed in liver and kidney, respectively. 
Hepatic metformin concentrations were approximately eight-
fold lower in Oct1-knockout mice, as compared with wild-type 
mice, despite similar concentrations of metformin in the plasma, 
consistent with the hypothesis that OCT1 controls intracellular 
Table 1 Examples of studies in which membrane transporters have been shown to alter hepatocellular drug concentrations
Transporter 
(gene)
localization  
and 
directionality substrate
effect on 
intracellular 
concentrationsa
effect on  
plasma 
exposurea observationb model system
MRP2  
(ABCC2)
Canalicular 
efflux
99mTc-Mebrofenin ↑ NA Prolonged and increased  
hepatobiliary exposure in patients  
with genetically impaired MRP2 
function23
Humans in vivo
7-Hydroxymethotrexate ↑ ↑ Hepatic accumulation of 
7-hydroxymethotrexate26
Mrp2−/− mice
Valproate glucuronide ↑ NA Inhibition by probenecid increased 
hepatic exposure27
Isolated perfused rat 
livers
MRP3  
(ABCC3)
Basolateral 
efflux
7-Hydroxymethotrexate ↑ ↑ Pronounced accumulation of 
7-hydroxymethotrexate26
Mrp2−/−/Mrp3−/− 
mice
Valproate glucuronide ↑ NA Inhibition by probenecid increased 
hepatic exposure27
Isolated perfused rat 
livers
Unconjugated bile acids ↓ ↑ Induction by ANIT decreased  
hepatic concentrations29
Mice
BCRP  
(ABCG2)
Canalicular 
efflux
Rosuvastatin (↑) NA Reduced-function polymorphisms 
increased hepatic efficacy24,25,76
Humans in vivo
Nitrofurantoin ↑ NA RNA interference knockdown  
reduced in vitro biliary clearance77
Sandwich-cultured 
rat hepatocytes
OCT1  
(SLC22A1)
Basolateral 
uptake
Metformin (↓) ↔ Reduced-function polymorphisms 
limited the pharmacological  
effect20
Humans in vivo
Metformin ↓ ↔ Reduced hepatic concentrations18 Oct1−/− mice
OATP1B1 
(SLCO1B1)
Basolateral 
uptake
Methotrexate (↓) ↑ Reduced-function polymorphisms 
decreased gastrointestinal toxicity and 
increased plasma concentrations78
Humans in vivo
Methotrexate ↓ ↑ Decreased hepatic concentration  
and increased plasma exposure70
Oatp1a−/−/1b−/− 
mice
Gadoxetate disodium  
(MRI contrast agent)
↓ NA Inhibition by lapatinib decreased 
hepatic parenchymal  
enhancement17
Humans in vivo
Pravastatin ↓ ↑ Decreased hepatic concentrations79 Oatp1a−/−/1b−/− 
mice
MATE1 
(SLC47A1)
Canalicular 
efflux
Metformin ↑ ↑ Increased hepatic concentrations80 Mate1−/− mice
NA ↔ Reduced-function polymorphic  
variants enhanced glucose-lowering 
effects of metformin81
Humans in vivo
ANIT, alpha-naphthyl isothiocyanate; AUC, area under the concentration–time curve; BCRP, breast cancer–resistance protein; MATE, multidrug and toxin extrusion protein; MRI, 
magnetic resonance imaging; MRP, multidrug-resistance protein; NA, data are not available; OATP, organic anion–transporting polypeptide; OCT, organic cation transporter.
aUp and down arrows indicate increased and decreased intracellular concentrations (or plasma AUC), respectively. Left–right arrows indicate no significant change.  
Parentheses denote examples for which the effect on intracellular concentrations is not directly measured but instead implied from pharmacological or toxicological 
observations. bRefs. 76–98 are listed in Supplementary Data online.
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hepatocyte concentrations of metformin.18 However, increased 
systemic concentrations due to decreased clearance or altered 
distribution and elimination pathways, in conjunction with 
impaired hepatic uptake, may result in little net change in 
hepatic drug exposure (area under the concentration–time 
curve (AUC)liver). For example, in one study, metformin hepatic 
exposure was decreased only modestly (knockout-to-wild-type 
ratio of ~0.6) in Oct1−/−/Oct2−/− mice.19 In humans, reduced-
function genetic polymorphisms of OCT1 could also decrease 
the therapeutic response of metformin, although the clinical 
relevance of these variants remains to be established in large-
scale studies.20
Increased hepatocyte concentrations due to impaired 
 canalicular excretion and/or basolateral efflux
Hepatic drug/metabolite exposure is expected to increase 
asymptotically with increasing impairment of hepatic excretory 
transport for compounds that are substrates for efflux trans-
porters.21 This relationship has been supported by data gener-
ated in isolated perfused rodent liver studies, in which liver, 
perfusate, and biliary concentrations of anionic substrates were 
measured under various scenarios of impaired efflux transport. 
The hepatobiliary imaging agent 99mTc-mebrofenin, an imino-
diacetic acid analog, is taken up efficiently into hepatocytes by 
OATP1B1 and OATP1B3 and preferentially excreted into bile by 
the canalicular multidrug-resistance protein 2 (MRP2/ABCC2); 
99mTc-mebrofenin is also a substrate for the basolateral efflux 
transporter MRP3 (ABCC3).22 Humans with impaired MRP2 
function (Dubin–Johnson syndrome) exhibit increased and 
prolonged hepatic exposure to 99mTc-Mebrofenin and other 
iminodiacetic acid analogs.23 Some statins are also substrates 
for MRP2 and breast cancer–resistance protein (BCRP/ABCG2). 
Impaired statin excretion from the hepatocyte due to reduced 
canalicular transport would be expected to result in higher 
intracellular exposure and increased efficacy.2 In fact, patients 
expressing at least one reduced-function ABCG2 variant 
421C>A (rs2231142) allele were more likely to achieve the low-
density lipoprotein (LDL) cholesterol target after rosuvastatin 
treatment, as compared with simvastatin treatment, but this dif-
ference between treatments was not significant for carriers of 
the reference allele.24 In addition, carriers of the 421C>A allele 
exhibited increased plasma AUC values and higher peak plasma 
concentrations of rosuvastatin.25 However, because BCRP is also 
expressed in the intestinal epithelium, this effect may be related 
to increased intestinal absorption in addition to decreased bil-
iary clearance.
Under normal conditions, canalicular MRP2 functions in 
a complementary manner with basolateral MRP3 and MRP4 
(ABCC4) to maintain low intracellular concentrations of 
endogenous and exogenous organic anions. Altered function 
of these efflux transporters due to genetic mutations, disease 
state alterations, or DDIs may affect hepatocyte exposure to 
substrates. For example, the toxic metabolite of methotrexate, 
7-hydroxymethotrexate, accumulated extensively in the livers 
of Mrp2−/− mice; accumulation was even more pronounced in 
Mrp2−/−/Mrp3−/− mice.26 Probenecid-mediated inhibition of 
these same transporters was postulated to be responsible for the 
increased hepatocyte concentrations of valproate glucuronide 
observed in isolated perfused rat livers following probenecid 
and valproate coadministration.27
Decreased hepatocyte concentrations due to increased 
 basolateral efflux
Induction of basolateral efflux transporters in disease states such 
as cholestasis or nonalcoholic fatty liver disease28 may result in 
decreased hepatocyte exposure to substrates. Although clini-
cal observations are limited, animal studies have shown altered 
hepatic exposure as a result of induced basolateral efflux trans-
porters. Mice treated with the cholestatic agent alpha-naphthyl 
isothiocyanate exhibited increased plasma concentrations and 
decreased hepatic concentrations of unconjugated bile acids, 
consistent with increased hepatic basolateral Mrp3 expression;29 
however, interpretation of this finding is complicated by parallel 
decreases in the expression of basolateral uptake transporters 
that may transport bile acids.
Increased hepatocyte concentrations due to transporter-
mediated intracellular sequestration
Membrane transporters are increasingly recognized as impor-
tant determinants of local drug concentrations in subcellu-
lar domains and organelles. For example, cellular toxicities 
of antiviral agents have been linked to local accumulation in 
mitochondria as a result of transport via equilibrative nucleo-
side transporters (SLC19).30 Other transport proteins may be 
involved in the subcellular localization of drugs,31,32 but data in 
hepatocytes are lacking.
Effects of drug-metabolizing enzymes and their interplay 
with transporters
Many drugs undergo extensive metabolism in the hepatocyte 
via the action of cytochrome P450s (CYPs; phase I metabolism) 
and/or conjugation by uridine 5′-diphospho–glucuronosyltrans-
ferases, sulfotransferases, and/or glutathione S-transferases 
(phase II metabolism). These enzymes are highly enriched in 
the liver and are involved in the elimination, detoxification, 
or activation of various endo- and xenobiotics.33 Importantly, 
there is significant overlapping of substrate specificity between 
hepatic enzymes and transporters. For instance, some drugs, 
such as atorvastatin and repaglinide, are substrates of both CYP 
enzymes and OATP1B uptake transporters.34 Most phase II con-
jugates are substrates of canalicular (e.g., MRP2, BCRP) and/
or basolateral (e.g., MRP3) efflux transporters, which mediate 
the active transport of these metabolites into the bile or blood, 
respectively.35 Thus, the interplay between hepatic transporters 
and enzymes is a complex process that can modulate systemic 
and hepatocyte concentrations of drugs and metabolites, as well 
as endobiotics.36
In general, basolateral uptake and efflux transporters  regulate 
the extent of intracellular drug accumulation. Enzymes and 
canalicular efflux transporters modulate cellular concentra-
tions via metabolism and biliary excretion. Studies of  isolated 
perfused rat livers with digoxin, a substrate for rat hepatic 
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Oatp1a4, P-glycoprotein (P-gp), and Cyp3A, have demonstrated 
the interplay between metabolism and transport in determining 
hepatic digoxin exposure.37 Rifampin reduced hepatic exposure 
of digoxin to Cyp3A by inhibiting basolateral uptake mediated 
by Oatp1a4. By contrast, quinidine slightly decreased hepatic 
exposure of digoxin and significantly increased the levels of 
the digoxin metabolite Dg2 and the ratio of Dg2 to digoxin in 
the liver. These findings are consistent with inhibition of P-gp-
mediated canalicular excretion of digoxin, which results in 
increased availability to and, subsequently, increased metabo-
lism by Cyp3A.37 Erythromycin, a commonly used probe for 
CYP3A4 activity, is also a substrate for MRP2 and P-gp. In a 
study in cancer patients, a common reduced-function variant 
of MRP2 (24C>T; rs717620) was found to be associated with 
increased erythromycin metabolism on the basis of the erythro-
mycin breath test. This effect was attributed to increased hepatic 
residence time of erythromycin due to a reduction in MRP2-
mediated biliary secretion.38 Collectively, these data are in agree-
ment with results from physiologically based pharmacokinetic 
(PBPK) modeling studies demonstrating that decreased uptake 
transporter activity may decrease the rate (and thus extent) of 
metabolism, assuming that hepatic uptake is the major contribu-
tor to systemic elimination. By contrast, decreased activity of 
biliary transporters would be expected to increase the rate of 
metabolism under linear kinetic conditions due to competition 
for intracellular substrate concentrations between biliary efflux 
transporters and enzymes.39
In summary, studies illustrating the effect of transporters and 
enzyme–transporter interplay on hepatic exposure of drugs and 
their metabolites are often conducted using in vitro cultured 
hepatocytes, in situ isolated perfused livers, or transporter-
knockout animals. Data from these model systems may be 
confounded, for example, by in vitro conditions that are rela-
tively simplistic as compared with the complexity of the in vivo 
system, species differences, and the possibility that knockout 
models may show compensatory alterations in metabolic and/
or transport pathways. Generally, data that directly demonstrate 
transporter effects and enzyme–transporter interplay in humans 
are sparse owing to the technical challenges involved in directly 
measuring intracellular and bile concentrations of drugs/metab-
olites in vivo in human livers. The interaction (e.g., inhibition 
or induction) with transporters/enzymes in other organs, such 
as the gastrointestinal tract or kidney, coupled with the often 
nonselective inhibitory profiles of coadministered medications, 
may complicate the interpretation of in vivo clinical data. In 
this regard, PBPK modeling may be useful to interpret and pre-
dict such complex transporter effects and enzyme–transporter 
interplay as well as the impact on hepatic exposure of drugs and 
metabolites under different scenarios.39
EXPERIMENTAL METHODS FOR MEASURING INTRA­
CELLULAR DRUG CONCENTRATIONS
The in vitro, in situ, and in vivo models that potentially can 
be applied to estimate unbound hepatocyte concentrations 
of drugs and metabolites are summarized in Table 2, along 
with the major applications and limitations of these models. 
In most cases, these models cannot provide direct estimation 
of unbound hepatic drug concentrations in humans, but the 
data generated can be applied as input kinetic parameters for 
mechanistic modeling to predict intrahepatic concentrations. 
With the availability and application of analytical tools that 
accommodate femtoliter-level sample volumes and submicron-
scale image resolution, direct measurements of intracellular 
concentrations are becoming more realistic. Current and 
future experimental methodologies that provide qualitative 
or quantitative measurements of intracellular drug concentra-
tions are summarized in Table 3 and discussed below. These 
include indirect methods, which require a modeling approach 
to estimate the amount of intracellular drug, and direct meth-
ods, which provide quantification of drug in defined cellular 
or subcellular volumes. To date, many of these techniques are 
not established for the intracellular measurement of drug mol-
ecules in hepatocytes. However, published examples have been 
provided that illustrate potential future applicability to drugs 
and metabolites.
Indirect methods
Tissue homogenization. The amounts of drug extracted from 
tissue homogenate and a corresponding blood sample have 
been used to describe drug partitioning, to differentiate active 
vs. passive tissue uptake, and to derive pharmacokinetic 
parameters for compartmental models, including uptake and 
efflux clearances. Although convenient, this approach fails to 
acknowledge the various compartments (e.g., bile and sinusoi-
dal blood), cell types, and subcellular organelles within which 
drug molecules often distribute heterogeneously. Therefore, 
determination of hepatic intracellular drug concentrations 
using this approach may be misleading.40 This has been 
addressed in part by tissue homogenate dilution, fractionation, 
and equilibrium dialysis to determine subcellular localization 
and intracellular unbound drug concentrations using brain 
and liver samples.11,41
Fraction unbound in hepatocytes. The unbound fraction of drugs 
in hepatocytes is generally determined using equilibrium 
dialysis techniques, followed by quantification of drug concen-
trations via standard analytical techniques, such as high-per-
formance liquid chromatography–tandem mass spectrometry, 
in hepatocytes where metabolic activity has been inhibited.42 
This methodology is applicable to hepatocyte experiments with 
compounds that are metabolically cleared and whose entry 
into hepatocytes is not limited by hepatic uptake.43 However, 
for compounds for which entry into the hepatocyte is limited 
by permeability, intracellular unbound fractions cannot be 
determined using this methodology. Intracellular unbound 
hepatocyte concentrations in the presence of an active trans-
port mechanism have been estimated by simultaneously fit-
ting experimental data determined across a range of drug 
concentrations and time points.44 This modeling approach 
is discussed in more detail below. Alternatively, intracellular 
unbound drug concentrations have been quantified in vitro 
through parallel measurements of intracellular bound and 
ClInICal pHarmaCology & THerapeuTICs | VOLUME 94 NUMBER 1 | JULY 2013 131
Review
total drug concentrations in cultured cell lines13 and in sus-
pended9 and sandwich-cultured hepatocytes.41
Tomography imaging. Whole-body, noninvasive imaging meth-
ods, such as single-photon emission computed tomography and 
positron emission tomography (PET) imaging, are widely used 
to assess biodistribution and have been applied to the meas-
urement of hepatobiliary excretion.45,46 These imaging modal-
ities offer an advantage over tissue homogenization in terms 
of increased resolution to suborgan-level compartments and 
the ability to serially sample the same subject. However, they 
rely on measurements of radiolabeled drug divided by a theo-
retical volume that includes the combination of intravascular, 
extracellular, and intracellular compartments. Radiochemical 
modification of the test article with a particle-emitting probe 
(e.g., 18F, 11C, 89Zr, and 124I) could theoretically alter the dis-
tribution properties or transporter affinity of the molecule. In 
addition, differentiation between parent and metabolite usu-
ally is accomplished only through pharmacokinetic modeling.
Microdialysis. Microdialysis is limited in application and pro-
vides data from extracellular fluids to indirectly estimate 
intracellular drug concentrations. This primarily preclinical 
technique is typically used to measure unbound drug concen-
trations in the brain, but it also has been applied for measure-
ment of unbound drug in the bile.47 Assumptions regarding 
equilibrium dynamics, permeability, and the role of active vs. 
passive processes govern the utility of this technique and limit 
its applicability to calculations of intracellular drug concentra-
tions. An interesting approach that provides a better estimate 
of intracellular drug concentrations is PET imaging combined 
with microdialysis.48 In this approach, a microdialysis probe is 
placed in the tissue/region of interest during a dynamic PET 
scan, thus enabling measurement of unbound drug concentra-
tions in the extracellular space corresponding to the PET data.
Microautoradiography. Microautoradiography tracks the dis-
tribution of radiolabeled molecules in tissues and cells in 
culture.49 The technique has traditionally been used in con-
junction with quantitative whole-body autoradiography for 
research on absorption, distribution, metabolism, and excre-
tion during drug development. Resolution in microautoradi-
ography is generally of multicellular scale, but the technique 
has been shown to be useful for the study of single-cell micro-
organisms and can be applied to hepatic drug quantification.
Fluorescence imaging. Traditionally, quantitative chemical 
imaging methods have been used to study the distribution 
of fluorescent or pigmented dye molecules in cells or tissue 
samples. By combining optical (transmitted light or fluores-
cence) imaging microscopy with quantitative computational 
analysis techniques, spatial variations in the absorbance of a 
tissue sample, or in the fluorescence excitation and emission 
of a tissue  sample, can be converted to relative differences in 
the spatial distribution of an optical probe. Recently, addi-
tional  deep- tissue-imaging techniques have been developed 
to  facilitate the study of fluorescent probes in cells and live 
animals. However, only a handful of drugs fluoresce in the 
visible wavelengths or are pigmented sufficiently to allow 
detection above the endogenous background of tissue sam-
ples. Therefore, the application of fluorescence or absorbance 
imaging techniques holds very limited promise for pharma-
cokinetic analysis of subcellular drug disposition in the liver.
Direct methods
Currently, there are no established methods that can be used 
to directly measure subcellular drug concentrations in the 
liver. In hepatocytes, measuring drug concentrations in dif-
ferent subcellular compartments by direct chemical analysis is 
complicated by the small volumes and the dynamic nature of 
transport and retention phenomena that can be perturbed by 
invasive measurement schemes. As an alternative, noninvasive 
in vitro, in vivo, and ex vivo quantitative, microscopic–chemical 
imaging approaches have been developed. These methods could 
potentially be used to measure drug concentrations in hepato-
cytes (Table 3). The following techniques seem most promising 
and relevant.
Capillary electrophoresis.  To our knowledge, capillary electro-
phoresis (CE; Table 3) is the only direct subcellular analysis 
method that can be used to monitor the subcellular distribu-
tion of chemical agents in the hepatocytes of live animals.50 
In CE, whole cells and subcellular organelles are drawn into 
a capillary tube through electrokinetic or siphoning methods. 
Although CE requires cell disruption before measurement, the 
nature of this technique could theoretically provide analytical 
results within seconds after disruption, minimizing the effect 
of drug diffusion during the process. Chemical agents in the 
capillary are then measured with any one of a variety of highly 
sensitive detection methods, including laser-induced fluores-
cence, absorbance, and electrochemical and mass spectrome-
try.51,52 Nevertheless, although CE can be used to measure the 
amount of drug associated with a specific organelle fraction, 
drug concentration is also dependent on organelle volume.
Microscopic optical imaging.  To visualize the subcellular distri-
bution of unlabeled small-molecule drugs, Raman confocal 
microscopy is perhaps the most promising and broadly appli-
cable technique (Table 3). Although this optical imaging tech-
nique can be used to monitor the relative intracellular mass 
distribution of small molecules, it could potentially be com-
bined with independent calibration and volume measurements 
using three-dimensional reconstructions of confocal sections 
through a cell or tissue slice to calculate the concentrations of 
these molecules in individual subcellular compartments.
Microscopic mass spectrometry imaging.  Secondary ion mass spec-
trometry (SIMS) measurements are performed by directing a 
primary, micron-, or nanometer-diameter ion beam of a few 
kiloelectron volts of energy onto the surface of a solid tissue 
section to form secondary ions reflecting the atomic composi-
tion of the surface (Table 3). These secondary ions are then 
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Table 2 In vitro, in situ, and in vivo models to estimate the intracellular concentrations of drugs and metabolites in the liver
model system advantages Disadvantages examples of parameters estimateda
Membrane 
vesicles
•   Specific cell membrane or transporter  
protein can be studied in isolation
•   Substrate can have direct access to 
transporter-binding site
•   Direct correlation between 
transport kinetics and intracellular 
concentrations has not been 
extensively studied
•   Variations between batches
•   Not possible to directly measure 
intracellular hepatic concentrations
•   Canalicular efflux of pravastatin 
through Mrp2 was quantified using rat 
canalicular membrane vesicles: in vitro 
biliary clearance (in vitro CLbile) was 
estimated2
Recombinant 
proteins
•   Simple experimental design and rapid 
generation of test system
•   Identification of vectorial transport of 
substrates in polarized system
•   Kinetic parameters can be generated for  
PBPK models to estimate intracellular  
hepatic concentrations
•   Not possible to directly measure  
intracellular hepatic concentrations
•   For polarized systems, permeation across 
second membrane can be rate limiting, 
leading to the requirement for complex 
kinetic models
•   Intracellular accumulation of ezetimibe 
and metabolites measured in cell 
lines expressing OATP1B1, UGT1A1, 
and MRP2 using both radiolabel and  
LC–MS/MS82
Hepatocytes •   Direct measurement of initial uptake  
rate and intracellular concentrations
•   Many parameters can be determined  
from a single liver because a large  
number of cells will be available
•   Loss of polarity in suspension •   Intracellular concentrations of 
glutathione determined using capillary 
electrophoresis–laser-induced 
fluorescence83
•   In vitro studies to assess the impact 
of hepatic uptake transporters 
compared with passive diffusion 
into rat hepatocytes. Kpuu and CLdiff, 
along with other parameters, were 
estimated2
•   Parameters describing hepatic uptake (both 
active and passive) and intracellular binding 
were estimated44,63
Sandwich-
cultured 
hepatocytes
•   Polarity of hepatocytes is restored. Bile 
canalicular structures are formed, thus 
allowing vectorial transport across the 
hepatocytes
•   Direct measurement of intracellular 
 in vitro hepatic concentrations possible
•   Expression of transporters and  
drug-metabolizing enzymes can  
increase/decrease during culture
•   Estimation of kinetic parameters to 
describe disposition of parent compound 
and metabolites84
•   Parameters describing hepatic uptake 
(both active and passive) and biliary 
efflux were estimated for several OATP 
substrates61
Perfused liver •   Direct measurement of intracellular  
hepatic concentrations possible
•   Architecture of the liver remains intact
•   Extrahepatic processes cannot influence 
outcomes
•   Perfusion of human livers is not feasible
•   Viability of liver will decline throughout  
the duration of experiment
•   The experiments are labor intensive
•   Estimation of fu,liver and other kinetic 
parameters to describe hepatic 
disposition of parent compound and 
metabolites of both pafuramidine and 
CPD-086884
•   The impact of Oatp and Mrp2 on 
the intrahepatic concentrations 
of benzyloxypropionic 
tetraacetate were measured by 
γ scintillation probe, with kinetic 
parameters estimated for uptake and 
biliary efflux85
•   Impact of hepatic uptake and efflux on the 
exposure of digoxin to hepatic metabolism 
(Cyp3a). Liver-to-perfusate ratios were 
measured37
Animal models •   Direct measurement of hepatic  
concentration possible
•   Architecture of liver remains intact
•   The effect of individual transporters 
can be determined from mutant 
strains of animals; however, data 
may be confounded by alterations in 
compensatory pathways
•   Species differences in expression levels  
and substrate recognition
•   Exposure of liver to methotrexate by 
microdialysis86
Table 2 Continued on next page
ClInICal pHarmaCology & THerapeuTICs | VOLUME 94 NUMBER 1 | JULY 2013 133
Review
analyzed by mass spectrometry. Although SIMS can be used to 
monitor the relative spatial distribution of drug molecules with 
nanometer resolution, sample preparation involving fixation 
or freezing could lead to artifacts affecting drug distribution. 
Matrix-assisted laser desorption ionization, which utilizes soft 
ionization of sample surfaces using ultraviolet or infrared laser 
coupled with time-of-flight mass spectrometry, currently lacks 
the sensitivity to yield subcellular resolution.
Particle-induced photon emission.  Similar to SIMS, micro-PIXE 
(particle-induced X-ray emission) and micro-PIGE (particle-
induced gamma ray emission)53,54 are two additional micro-
scopic chemical imaging techniques that could be used to 
detect the subcellular distribution of drugs in hepatocytes 
based on quantifying the emission of photons that are pro-
duced upon interaction of an ion beam with a tissue surface. 
As in SIMS, sample preparation involving fixation or freezing 
could be problematic and may lead to artifacts.
As described above, direct methods to measure intracellular 
drug concentrations are not routinely available. Instead, there 
are established, indirect methods for measuring drug concen-
trations in the liver that provide parameters for mathematically 
modeling drug concentrations in the hepatocytes. These mod-
eling techniques are discussed in the following section.
ESTIMATION OF INTRACELLULAR DRUG CONCENTRATIONS 
BY MODELING AND SIMULATION
Modeling and simulation are a useful approach to estimating 
unbound intracellular drug concentrations in different tissues. 
Currently, reported modeling and simulation methods use phys-
icochemical properties of drugs, in vitro cell-based data such as 
passive permeability, cellular uptake/efflux, or in vivo animal 
and human pharmacokinetic data applied for estimation/refine-
ment of certain parameters using PBPK modeling approaches. 
Models that can reasonably delineate the impact of transporters/
enzymes on cellular or in vivo disposition provide useful esti-
mates of intracellular concentrations, but all involve a number 
of assumptions. Although integration into models of tissue con-
centration data obtained by advanced experimental methods as 
highlighted above is currently limited, it represents a key step for 
further refinement of the existing models and their validation.
Estimation of unbound intracellular drug concentration 
based on physicochemical properties
When permeation of drugs into cells is driven primarily by passive 
diffusion, steady-state partitioning into a cell can be reasonably 
predicted using logD7.4 for acidic compounds and logP for basic 
and neutral molecules. These empirical models have been used to 
predict the unbound fraction in both microsomes and hepatocytes 
(Table 4, methods 1 and 2). More recently, an empirical relation-
ship was defined between fu,cell values obtained by mechanistic 
modeling and logD7.4 using uptake data from either suspended or 
plated hepatocytes (Table 4, methods 3 and 4, respectively). This 
empirical relationship was established for a series of acidic and 
neutral drugs, many of which are substrates for hepatic uptake 
transporters.10,44 Extending these results, another recent study 
reported a multivariate structure-binding relationship based on 
fu,cell measurements in cultured cells.13 Although empirical, these 
approaches can provide an initial estimate of the fu,cell for a trans-
porter substrate before further mechanistic modeling.
The physicochemical characteristics of drugs can determine 
their unique intracellular distribution/accumulation. For exam-
ple, basic and cationic drugs can differentially distribute into 
lysosomes and mitochondria, respectively.11,13,14 Consideration 
of lysosomal partitioning in hepatocytes has been reported for 
lipophilic basic drugs (e.g., fluoxetine),12 but a more detailed 
analysis has been provided for brain tissue,11 for which inclu-
sion of pH partitioning into the cell and lysosomes with a 
Knockout  
animal models
•   Complete system where the impact of the 
abolition of one or more pathways can be 
explored
•   Impact of one pathway can be determined; 
however, up- or downregulation of other 
pathways may occur
•   Differences in exposure of digoxin in liver 
and other tissues were determined by bulk 
tissue analysis via radiometric endpoints87
•   Hepatic exposure of metformin in Oct1−/− 
relative to wild-type mice18,19
•   Effects of Mrp2 and/or Mrp3 on the hepatic 
exposure of methotrexate and its 7–OH 
metabolite; liver-to-plasma ratios (Kp) were 
estimated26
Human in vivo 
studies
•   Complex system; however, potential to 
determine intracellular concentrations is a 
possibility that may be realized
•   Direct measurement of unbound  
intracellular drug concentrations is 
challenging
•   PET imaging of hepatobiliary processes46
•   Imaging and pharmacokinetic 
modeling of hepatic levels of 99mTc-
mebrofenin22
•   99mTc-mebrofenin–ritonavir hepatic 
DDI evaluated in humans based on 
imaging data, in vitro IC50 values, 
and intracellular unbound ritonavir 
concentrations72
DDI, drug–drug interaction; fu,liver, fraction unbound in the liver; IC50, half-maximal inhibitor concentration; Kpuu, hepatocyte-to-medium partition coefficient for unbound drug 
concentration; LC–MS/MS, liquid chromatography–tandem mass spectrometry; OATP, organic anion–transporting polypeptide; PET, positron emission tomography; PBPK, 
physiologically based pharmacokinetic.
aRefs. 76–98 are listed in Supplementary Data online.
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three-compartment model accounted for the difference in 
the fu between brain slices and brain homogenates. In tumor 
cells, more than 90% of cellular MKT-077, a lipophilic cation, 
was estimated to reside in mitochondria;14 modeling of the 
intracellular concentration of MKT-077 was performed using 
the equations detailed in Method 7, Table 4. Further investiga-
tion of such mechanistic cellular models and their applicability 
to hepatocytes is required.
Table 3 Direct and indirect methodologies for the estimation of intracellular drug concentrations
Direct measurement methoda analyte/matrix Detection method utility/limitations/assumptions
Capillary electrophoresis51,52,88 “Bioparticles”, whole cells, 
organelles
Laser-induced fluorescence, UV, 
electrochemical, LC–MS
Nano- to femtoliter sample volumes 
required for analysis
Technically challenging and limited 
accessibility
Can isolate individual cells or organelles for 
analysis
Multiple techniques for different culture/
cell types
MSI: Nano-SIMS, MIMS89–91 Individual cells, potentially 
subcellular fractions, 
“bioparticles”
Secondary ion mass spectrometry,  
with mass analyzer, multi-isotope  
imaging mass spectrometry
Nano-SIMS 14C resolution potentially <0.1 µm
Nano-SIMS sensitivity could achieve 1,000 
times that of 14C autoradiography
Raman microscopy92–94 Analysis of cells and tissues, 
material surface 
Light scatter through change in 
polarization potential, rotation, or  
vibration energy
Probes’ vibrational states within chemical 
bonds
Applicable to biological systems with lower 
energy excitation for sample preservation
Recent, advanced detection systems 
have shortened data collection times for 
increased imaging throughput
Nuclear microscopy  
(microbeam PIXE/PIGE)53,54,95
Single cell; platinum and 
endogenous metals
Ion microbeam with  
particle-induced X-ray/γ-ray  
emission
Achieves ≤1-µm diameter resolution
Not a widely accessible technology
Limited to metal-containing drugs/
compounds (e.g., platinum drugs)
Microautoradiography49,96 Radiolabeled sample in 
cryosection
Exposure of radiolabel, FISH, IHC,  
confocal microscopy
Grain density evaluation can be combined 
with micro-FISH and confocal microscopy 
for structure–function analyses
Resolution generally limited to 
multicellular level
PET/SPECT imaging45,46,97 Positron/γ particle–emitting  
total drug or metabolite(s)  
in imaged tissue or organs  
of interest
PET/SPECT image with PK  
samples/LC–MS/LSC
Residualizing vs. nonresidualizing isotopes 
allow for derivation of internalization rate 
and concentration 
Receptor occupancy measurements 
possible
Expensive, technically challenging, limited 
by resolution to mathematically deriving 
concentrations in tissues
PET imaging with  
simultaneous microdialysis48
Same as PET plus  
microdialysate from  
volume of interest  
corresponding to PET scan
PET/in-line HPLC radioligand detector, 
γ-counter
Requires kinetic modeling to parameterize 
analyte flux and derive intracellular 
concentrations
Similar limitations as PET, yields small 
sample volumes
Requires physicochemical characterization 
of the test article to draw meaningful 
conclusions
Bulk analysis11,40 Total drug or metabolite(s) in 
tissue homogenate or section
HPLC–UV, LC–MS, radioactivity, MALDI Often fails to describe suborgan 
distribution
Pharmacokinetic model-based approach 
often used to derive intracellular 
concentrations from resultant data
Low-technology method and easily 
accessible
FISH, fluorescence in situ hybridization; HPLC, high-performance liquid chromatography; IHC, immunohistochemistry; LC–MS, liquid chromatography–mass spectrometry; 
LSC, liquid scintillation counting; MALDI, matrix-assisted laser desorption ionization; MIMS, multi-isotope imaging mass spectrometry; MSI, mass spectrometry imaging;  
PET/SPECT, positron emission tomography/single-photon emission computed tomography; PIGE, particle-induced γ-ray emission; PIXE, particle-induced X-ray emission;  
PK, pharmacokinetic; SIMS, secondary ion mass spectrometry; UV, ultraviolet.
aRefs. 76–98 are listed in Supplementary Data online.
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Monolayer cell–based permeability models
A common method to measure cellular permeability and trans-
port is to determine the flux across a cell monolayer. Monolayer 
systems have been used to identify efflux transporter substrates 
and to determine the kinetic constants for transport. Although 
hepatocytes do not have the required tight junctions needed 
for monolayer permeability experiments, both hepatocytes and 
monolayer models include passive permeability and active trans-
port, and the interactions between these processes may be similar 
for both cell systems. Several reports have used three-compart-
ment models to represent Caco-2 or Madin–Darby canine kidney 
cell monolayers,55–59 for which the three compartments repre-
sent the apical, cellular, and basolateral compartments. Three-
compartment models also have been applied to simulate the 
combinations of passive permeability, active uptake, and efflux 
transport, as well as to study metabolism in Caco-2 cells.58
Such mechanistic modeling of drug permeability has revealed 
the importance of local concentrations in the design and inter-
pretation of drug transport experiments for efflux transport-
ers such as P-gp and BCRP. Using elementary rate constants to 
model permeability across monolayer model systems, the actual 
Km (Michaelis–Menten constant) parameters for transporter-
mediated flux were shown to differ greatly55 from the appar-
ent Km obtained by fitting a Michaelis–Menten equation to the 
observed transport data (Km,app). Another report showed that 
kinetic parameters calculated from concentration–efflux data 
overestimate the half-maximal inhibitor concentration (IC50) and 
Km values.56 Moreover, using verapamil, quinidine, and vinblas-
tine as substrates, Km values determined based on intracellular 
concentrations calculated from a three-compartment model were 
consistent for different cell systems, whereas Km,app varied greatly 
with transporter expression.59 These reports suggest that the dif-
ferences in observed Km and Ki  (inhibition constant) values are 
due to changes in the intracellular concentration of substrates 
and inhibitors caused by the action of transporters. Use of calcu-
lated intracellular concentrations (instead of apical or basolateral 
concentrations) resulted in more consistent kinetic parameters.
Because the substrate-binding site of P-gp is accessed from 
within the inner leaflet of the apical membrane,60 the three-com-
partment model described above was extended to include explicit 
basolateral and apical membrane compartments.57 This model 
showed significant differences in predicted intracellular concen-
trations for apical vs. basolateral addition of drug. Apical efflux by 
P-gp resulted in very low intracellular concentrations following 
apical addition, whereas intracellular concentrations were lower 
by twofold or less after basolateral addition. These observed dif-
ferences are consistent with the impact of efflux transporters on in 
vivo drug concentrations in the brain (apical exposure) and liver 
(basolateral exposure). Although the intracellular concentrations in 
the above studies have not been confirmed experimentally by direct 
measurement, correlations among predicted intracellular concen-
trations, Km values, and tissue concentrations are encouraging.
Hepatocyte models to estimate unbound fraction
Studies that have attempted to assess the extent of intracel-
lular binding of transporter substrates in conjunction with 
multiple ongoing processes within hepatocytes are summarized 
in Table 4. One method to estimate the fu,cell value is indirectly 
from the Kp (hepatocyte-to-medium total drug concentration 
ratio) and Kpuu (hepatocyte-to-medium partition coefficient for 
unbound drug concentration) data.9,10 The parameter Kp reflects 
the extent of both intracellular binding and active transport 
processes, whereas Kpuu reflects only active transport. Certain 
studies incorrectly assume that Kp reflects an increase in cellular 
unbound drug concentration, which is subsequently available 
to metabolic enzymes. A study using suspended rat hepatocytes 
showed that no direct correlation could be established between 
Kpuu and fu,cell, highlighting the fact that the measurement of only 
one of these processes in isolation is insufficient to characterize 
drug distribution in hepatocytes.10 The importance of the Kpuu 
value for statins, which are taken up into hepatocytes by OATPs, 
is exemplified in interpreting the difference in the IC50 of statins 
for the inhibition of 3-hydroxy-3-methyl-glutaryl–coenzyme A 
reductase activity between the hepatocyte and the microsomal 
systems. Theoretically, the ratio of the IC50 values (microsome/
hepatocyte) of statins should be the same as their Kpuu values 
because only unbound drug will be responsible for the enzyme 
inhibition. The reported data seem to support this hypothesis.9
Recently, mechanistic two- or three-compartment models 
including media, cellular, and bile compartments have been 
applied.44,61–64 These models allow dynamic evaluation of mul-
tiple processes occurring in hepatocytes, including active trans-
port, passive permeability, efflux, and intra/extracellular binding. 
Unlike static models (e.g., the conventional two-step approach 
in which passive diffusion is measured separately and subtracted 
from the transport observed in a complex system), mechanistic 
compartmental models allow simultaneous fitting of all con-
centration–time points during uptake at 37°C and estimate the 
extent of intracellular binding as an output model parameter.44,63 
Intracellular binding is estimated in conjunction with other pro-
cesses, including metabolism, if the cellular concentrations of 
both parent and metabolite(s) are measured. The fu,cell in the 
mechanistic in vitro models can be obtained/predicted in some 
instances by other methods and implemented as a constant in the 
model, as shown recently in the analysis of sandwich-cultured 
hepatocyte uptake data.61 One of the assumptions in the current 
mechanistic compartmental in vitro models is that the intracel-
lular binding is not saturated at the substrate concentrations 
studied, which may lead to overestimation of the fu,cell value if 
saturation were to occur. These mechanistic models provide more 
dynamic and physiologically relevant characterization of cellular 
processes, but the main limitation is the requirement for a large 
number of data points/cells for appropriate parameter definition. 
Subsequently, estimated fu,cell values are applied as input param-
eters in the PBPK models to allow a mechanistic description of 
unbound drug concentrations in the liver.
PBPK models
Whole-body PBPK models integrate drug-related kinetic 
parameters and physiological parameters to predict drug 
disposition in vivo. PBPK models are useful to simulate 
not only blood (plasma) concentrations but also tissue 
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concentration–time profiles. This allows assessment of (i) 
potential drug-related efficacy and toxicity (e.g., statin pro-
files in the liver and muscle, respectively)2 and (ii) changes in 
systemic and liver exposure due to DDIs or genetic polymor-
phisms of transporter/enzyme proteins.
Most PBPK models consider tissues as well-stirred, perfu-
sion rate–limited compartments, i.e., the concentration of the 
unbound drug in the tissue is in equilibrium with the unbound 
concentration in the emergent blood.65,66 Although acceptable 
for many highly permeable drugs, a permeability rate–limited 
tissue model is often required to describe distribution of low-
permeability molecules. For these drugs, additional compart-
ments are included to account for vascular or cellular diffusional 
barriers.2,61,64–67 Figure 2b represents a generic permeability-
limited liver model that can be expanded to account for addi-
tional processes, if needed (e.g., basolateral efflux, organelle 
sequestration, or saturable binding (as in the case of cyclo-
sporine)).68 However, the model expansion and complexity 
depend on the availability of adequate tissue data to allow a 
mechanistic description of these processes and precise estima-
tion of the PBPK model parameters.68
Drug distribution within the liver is a complex process, and 
determining the steps that modulate hepatic exposure of drugs is 
important, as illustrated in Figure 3. For drugs with high passive 
diffusion and substantial metabolic elimination (e.g., saquinavir), 
profiles such as those simulated in Figure 3a–c are expected. 
However, for many drugs, active uptake from the blood into 
hepatocytes is the dominant process, in comparison with pas-
sive permeability, metabolism, or active efflux,10,63,69 resulting 
in unbound liver/blood concentration ratios greater than unity 
(Kpuu,liver >>1) (Figure 3f). In such cases, reduced activity in 
basolateral uptake transporters (due to either inhibition or poly-
morphism) leads to increased drug concentrations in blood and 
lower Kpuu,liver. However, the effect on liver exposure (expressed 
as AUCliver) will depend on whether alternative elimination routes 
exist: if hepatic elimination is the predominant route, AUCliver 
will be determined primarily by biliary excretion and metabolic 
clearance. In that case, reduced activity of the basolateral uptake 
Table 4 Summary of methodologies available to estimate intracellular fraction of unbound drug in cells
methoda predictive equations developed for fu,cell Comments
1.  Empirical prediction of fu for 
nontransporter substrates42
log(1- f )
f
0.40logD(P) 1.38u
u
= −
2.  Empirical prediction of  
fu,cell for nontransporter  
substrates98
f
1
1 (125 VR 10 )
u,hep 0.072logP(D) 0.067logP(D) 1.1262
=
+ × × + −
Thirty-nine acidic, neutral, and basic drugs
3.  Indirect estimation from  
Kpuu and Kp data for  
transporter substrates10
K
CL CL
CL
, f
K
Kpuu
act,uptake diff
diff
u,cell
puu
p
=
+
=
Empirical model for prediction of fu,cell developed 
using acidic and neutral drugs: Log fu,cell = −0.9161–
0.2567 logD7.4 (suspended hepatocytes)
4.  Mechanistic compartmental 
uptake model44,63
dC
dt
V C
K C
+CL C CL C
cell
max med,u
m,u med,u
diff med,u diff cell
=
×
+
× − × × f
V
u,cell
cell
fu,cell is the output parameter of the mechanistic 
model
Extended incubation times (45–90 min) required for 
precise fu,cell estimation
Empirical model for prediction of fu,cell developed 
using acidic and neutral drugs: Log fu,cell = −0.4379–
0.4129 logD7.4 (plated hepatocytes)
fu,cell Obtained using extensive rat hepatocyte studies 
can be applied for the analysis of human hepatocyte 
uptake data
5.  Mechanistic compartmental 
uptake and metabolism 
model44,63 dC
dt
V C
K C
CL C C f
cell
max med,u
m,u med,u
diff med,u cell u,cel
=
×
+
+ × − × l diff met,u
cell
CL CL
V
× +( )
6. pH partitioning11 K = V +K (V + V K )puu,cell ISF puu,cyto ISF lyso puu,lyso
Kpuu,cyto and Kpuu,lyso are determined by pH partition 
theory
7.  Model based on plasma 
membrane potential and 
mitochondrial uptake14
C = 1 + V e C (1 e )cell 0,med
tβ −γ κ( ) Cellular concentration of unbound fraction (Ccell,u) 
estimated using total concentration and cytosol/
mitochondria equilibrium constant (β), which is 
determined from the C(t) profileκ = + β − γ  k / 1   1  eγ ( )( )
C = C/ 1 + cell,u β( )
C0,med, initial drug concentration in medium; Ccell, total cellular concentration; CLact,uptake, intrinsic active uptake clearance; Cdiff, passive diffusion clearance; Cmed,u, unbound 
drug concentration in medium; CLmet,u, unbound metabolic clearance; dC/dt, the differential form describing the rate of change in concentration with respect to time; fu, fraction 
of unbound drug; fu,cell, fraction of unbound drug in cell; fu,hep, fraction of unbound drug in hepatocyte incubations; k, mass transfer coefficient across the cell membrane; Km,u, 
unbound drug affinity constant; Kp, the membrane partition coefficient, which can be measured as the hepatocyte-to-medium total drug concentration ratio; Kpuu, hepatocyte-
to-medium partition coefficient for unbound drug concentration; Kpuu,cyto, ratio of concentration of the unbound fraction in the cytosol to that in brain interstitial fluid (ISF) ; 
Kpuu,lyso, ratio of concentration of the unbound lysosomal fraction to that of the unbound cytosolic fraction; Vcell, intracellular volume; VISF, volume of the brain interstitial fluid; 
Vlyso, volume of the lysosome; Vmax, maximum transport or metabolic rate; γ, constant associated with plasma membrane potential.
aRefs. 76–98 are listed in Supplementary Data online.
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transporter will lead to a decrease in Cmax,liver and a prolonged 
terminal half-life, but the AUCliver value will remain unchanged 
(Figure 3e). In contrast, inhibition of either biliary transporters 
or metabolism could have a pronounced effect on liver exposure 
(e.g., pravastatin).2 If renal clearance is a significant contributor to 
the total drug clearance, liver and plasma exposure will be affected 
by multiple mechanisms, including not only hepatic basolateral 
uptake, metabolism, and/or biliary excretion but also renal elimi-
nation (as in the case of methotrexate,70 Table 1). A recent clinical 
microdose study performed in the presence of either OATP1B or 
CYP3A4 inhibitors71 supported the principles stated above for 
atorvastatin, but clinical data delineating the relative importance 
of OATPs and metabolism are lacking for most other drugs. The 
interplay between these processes is very complex, and direct 
measurement of exposure in liver and other human tissues is cru-
cial to further validate this model because systemic exposure data, 
in many cases, are not an adequate surrogate for tissue concen-
tration–time profiles. Clinical studies using PET/single-photon 
emission computed tomography imaging and other advanced 
experimental methods in conjunction with mechanistic modeling 
may help refine our understanding of tissue distribution of a drug 
and its implications.45,72
For a PBPK model to accurately predict drug disposition 
(including intracellular concentrations), mechanistic input 
parameters from in vitro cellular systems (e.g., active uptake/
efflux, passive permeability, intracellular binding, and metabo-
lism) need to be integrated with systems parameters (e.g., abun-
dance of transporters and enzymes).2,64,67 In certain instances, 
the kinetic parameters related to hepatic clearance (active uptake 
or biliary excretion) can be estimated in vivo in rats.2 Despite 
species differences in transporter expression and activity,73 ini-
tial model optimization in rats can be useful for understanding 
the underlying mechanisms (e.g., enterohepatic recirculation 
of valsartan) and application as empirical scalars for human 
prediction.2,74 Further validation/refinement of the human 
PBPK models should be carried out when relevant clinical data 
become available. Use of PBPK model–simulated local tissue 
concentrations at the relevant sites of action (instead of plasma 
exposure as a surrogate) allows prediction of transporter- and 
transporter-metabolism-based DDIs in a more mechanistic 
manner. Examples include use of the unbound hepatic inlet 
concentrations for the assessment of the interaction potential 
on basolateral hepatic uptake transporters, liver intracellular 
concentrations for efflux transporters/enzymes, and enterocyte 
Figure 3 PBPK simulations of the unbound plasma and liver concentration–time profiles and the ratio of unbound liver tissue to liver sinusoidal concentrations 
(Kpuu,liver). A permeability-limited liver model was used for simulations to account for active transport processes. (a–c) Drugs with a large contribution of  
passive diffusion to total uptake and substantial metabolic elimination/biliary excretion. Profiles represent the impact of variation in hepatic elimination 
resulting in differential liver exposures, where the solid line represents CLmet (or CLbile); dashed line, 0.5× CLmet (or CLbile); and dashed-dotted line, 2× CLmet (or 
CLbile). (d–f) Active uptake is the major contributor to the total uptake (CLact,uptake > CLdiff > CLmet or CLbile). Variation in uptake transporter activity (solid line 
represents CLact,uptake; dashed line, 0.5× CLact,uptake; and dashed-dotted line, 2× CLact,uptake) results in differential blood exposure (d) with no effect on liver AUC 
(e) for drugs primarily cleared by liver, either via biliary excretion (e.g., pravastatin) or CYP450-mediated metabolism (e.g., repaglinide). (a–f) The drug is assumed 
to have a high extent of intracellular binding (fu,cell < 0.1) and minimal contribution of renal clearance to overall elimination. Changing the fu,cell in the PBPK 
model will affect the total liver concentration, but the overall trends will remain the same. AUC, area under the concentration–time curve; CLact,uptake, intrinsic 
active uptake clearance; CLbile, intrinsic biliary excretion clearance; CLdiff, passive diffusion clearance; CLmet, intrinsic metabolic clearance; fu,cell, unbound fraction 
of drug in cell; PBPK, physiologically based pharmacokinetic.
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concentrations for intestinal efflux transporters/enzymes, as 
conducted recently for the prediction of cyclosporine DDIs.67
CURRENT CHALLENGES IN MEASURING AND  PREDICTING 
INTRACELLULAR CONCENTRATIONS OF DRUGS AND 
 METABOLITES
Many challenges and knowledge gaps currently exist in deter-
mining the relevant hepatocellular concentrations of drugs and 
metabolites to accurately predict drug efficacy, toxicity, and clear-
ance (metabolic or biliary) difficult. In general, our understand-
ing of intracellular drug disposition in the liver is rudimentary. 
Although mathematical models commonly assume that the liver 
is a “well-stirred” compartment, subcellular distribution (e.g., 
lysosomal trapping and mitochondrial accumulation) may affect 
the intracellular concentration of some drugs, thereby influencing 
specific target binding, metabolism, and toxicity. How these pro-
cesses affect intracellular drug concentrations is not well under-
stood, especially at the kinetic level. Furthermore, the involvement 
of transporters in determining local drug concentrations in sub-
cellular domains and organelles remains generally unexplored. In 
fact, the fundamental definition of “intracellular concentration” is 
debatable. The unbound liver concentration, calculated as the sum 
of unbound drug mass in all hepatocyte compartments divided 
by the total cytosolic volume, may not accurately represent the 
relevant concentrations of most drugs at the sites of action (effi-
cacy), toxicity, and elimination.
Currently available in vitro and in vivo models have limited 
capability to quantitatively predict the impact of transporters on 
intracellular drug concentrations. In many cases, empirical scal-
ing factors need to be applied when extrapolating uptake/efflux 
transporter activity from in vitro to in vivo models in humans. 
For compounds that undergo hepatic metabolism, prediction 
of enzyme–transporter interplay adds another level of complex-
ity. In vitro models retaining the activity of hepatic basolateral 
uptake/efflux and canalicular transporters, in addition to drug-
metabolizing enzymes, may be required to accurately predict 
Kpuu,liver in humans. Recently, some three-dimensional cultured-
hepatocyte systems/microfluidic devices have been developed 
to mimic the in vivo architecture. Without direct measurement 
of in vivo hepatic pharmacokinetics, it is difficult to reconcile 
how these sophisticated models will provide better predictions 
of hepatocellular concentrations than traditional two-dimen-
sional sandwich-cultured hepatocytes. Transporter-knockout 
animal models provide a mechanistic understanding of the in 
vivo roles of transporters in determining both systemic and tis-
sue exposure to drugs. However, these models are limited by 
species differences in substrate specificity, tissue distribution, 
relative abundance of transporters, and potential compensatory 
mechanisms.75 The utility of animal models expressing human 
transporters and/or enzymes in predicting intracellular drug 
concentrations remains to be determined.
Currently, there are no standardized, accepted methods to 
directly measure unbound intracellular drug concentrations. 
Noninvasive approaches to measure unbound drug concentra-
tions in human tissues are limited. As a result, total drug concen-
trations in tissues and cell-based models are used as surrogate 
measurements and often are not correlated with unbound intra-
cellular drug concentrations. Therefore, using total drug concen-
trations to predict efficacy, toxicity, and DDIs can be misleading. 
Although some novel imaging techniques appear promising, in 
most cases these techniques have not been applied to quantifi-
cation of drug molecules in the liver microenvironment. In the 
future, techniques such as confocal Raman microscopy, nano-
SIMS, and CE may be used to spatially quantify the hepatocellular 
pharmacokinetics of drug molecules that do not contain a fluoro-
phore. However, these techniques may not be readily applicable 
to humans.
Significant progress has been made in using modeling 
approaches to predict the effect of drug-metabolizing enzymes 
and transporters on the systemic exposure of drugs in preclinical 
species and humans. However, the ability of these models to pre-
dict intracellular drug concentrations for transporter substrates 
is unknown. These models require certain assumptions, and the 
lack of methods to directly measure tissue concentrations of the 
unbound drug in humans makes it difficult to validate these 
assumptions and refine the predictions. Therefore, establishing 
a publicly available, peer-reviewed database of liver-to-plasma 
“steady-state” partition coefficients based on unbound drug con-
centrations in preclinical species and humans will be helpful. 
Furthermore, complicated mechanistic models require large in 
vitro and/or in vivo data sets to predict and simulate intracellular 
drug concentrations. The accuracy of models also relies on the 
quality of input parameters, which are extrapolated from in vitro 
and/or in vivo models; inaccurate conclusions may be drawn 
when too many unknown parameter values are estimated on the 
basis of too few measurements. Because of the lack of experience 
and high level of uncertainty, these complicated models are not 
currently applied routinely to new drug candidates.
SUMMARY
The intracellular concentration of the unbound form of a drug 
is an important parameter for predicting drug efficacy, toxicity, 
and DDIs. Although we have made great progress over the past 
two decades in elucidating the roles of transport proteins in drug 
disposition, many fundamental questions remain unanswered. 
In particular, understanding the impact of transporters on the 
modulation of intracellular drug concentrations is still a challeng-
ing area, representing an important direction for research in this 
field. This white paper highlights the importance of intracellular 
concentrations in drug development and provides an update on 
current progress, issues, and critical scientific gaps in quantitatively 
assessing intracellular drug concentrations by direct measurement 
or modeling/simulation. The unbound drug concentration in the 
liver is an important parameter used to predict (i) DDIs at the level 
of metabolic enzymes and transporters and (ii) drug-induced liver 
toxicity. Due to current limitations in existing experimental model 
systems and, more importantly, the lack of preclinical and clinical 
data to establish in vitro–to–in vivo correlations, it is premature to 
propose the use of predicted maximal intracellular unbound drug 
concentrations to avoid false-negative DDI predictions. Currently, 
uncertainties in intrahepatic drug concentrations, including those 
due to transporter activity, are addressed by incorporating safety 
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factors or using total (instead of unbound) plasma concentrations. 
Incorporation of Kpuu values would be expected to decrease these 
safety factors and improve the prediction of DDIs. Specific recom-
mendations regarding best practices to measure intracellular con-
centrations of new drug candidates include (i) direct measurement 
of total and unbound drug concentrations in whole liver tissue; 
(ii) determination of Kpuu in polarized hepatocytes, which have 
functional basolateral uptake/efflux transporters, metabolizing 
enzymes, and biliary efflux transporters; (iii) application of scaling 
approaches from hepatocytes to whole body based on these data; 
and (iv) use of PBPK modeling to assist in quantitative analyses 
and to make predictions. However, as detailed in this white paper, 
many of the technologies and approaches discussed above have 
limitations and/or are still under development. Continued techno-
logical and methodological innovation is necessary to expand our 
knowledge and to drive this field forward. Improved experimental 
models, development, and refinement of cutting-edge technologies 
(e.g., tissue imaging), as well as application of mechanistic mod-
eling approaches to estimate intracellular drug concentrations, will 
lead to more accurate predictions of drug efficacy, pharmacokinet-
ics, DDIs, and toxicities, ultimately enhancing the quality and use 
of drugs in the clinic.
SUPPLEMENTARY MATERIAL is linked to the online version of the paper at 
http://www.nature.com/cpt
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